Literature DB >> 20726905

HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study.

L D Rasmussen1, M Dybdal, J Gerstoft, G Kronborg, C S Larsen, C Pedersen, G Pedersen, J Jensen, L Pedersen, H T Sørensen, N Obel.   

Abstract

OBJECTIVE: The association between HIV infection and the risk of venous thromboembolism (VTE) is controversial. We examined the risk of VTE in HIV-infected individuals compared with the general population and estimated the impact of low CD4 cell count, highly active antiretroviral therapy (HAART) and injecting drug use (IDU).
METHODS: We identified 4333 Danish HIV-infected patients from the Danish HIV Cohort Study and a population-based age- and gender-matched comparison cohort of 43,330 individuals. VTE diagnoses were extracted from the Danish National Hospital Registry. Cumulative incidence curves were constructed for time to first VTE. Incidence rate ratios (IRRs) and impact of low CD4 cell count and HAART were estimated by Cox regression analyses. Analyses were stratified by IDU, adjusted for comorbidity and disaggregated by overall, provoked and unprovoked VTE.
RESULTS: The 5-year risk of VTE was 8.0% [95% confidence interval (CI) 5.78-10.74%] in IDU HIV-infected patients, 1.5% (95% CI 1.14-1.95%) in non-IDU HIV-infected patients and 0.3% (95% CI 0.29-0.41%) in the population comparison cohort. In non-IDU HIV-infected patients, adjusted IRRs for unprovoked and provoked VTE were 3.42 (95% CI 2.58-4.54) and 5.51 (95% CI 3.29-9.23), respectively, compared with the population comparison cohort. In IDU HIV-infected patients, the adjusted IRRs were 12.66 (95% CI 6.03-26.59) for unprovoked VTE and 9.38 (95% CI 1.61-54.50) for provoked VTE. Low CD4 cell count had a minor impact on these risk estimates, while HAART increased the overall risk (IRR 1.93; 95% CI 1.00-3.72).
CONCLUSION: HIV-infected patients are at increased risk of VTE, especially in the IDU population. HAART and possibly low CD4 cell count further increase the risk.
© 2010 British HIV Association.

Entities:  

Mesh:

Year:  2010        PMID: 20726905     DOI: 10.1111/j.1468-1293.2010.00869.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  20 in total

1.  HIV infection as a permanent, acquired risk factor for VTE.

Authors:  Michele Bibas; Gianluigi Biava; Andrea Antinori
Journal:  Nat Rev Cardiol       Date:  2014-04-08       Impact factor: 32.419

2.  Reply: Interaction between inherited thrombophilia and HIV infection: fact or fancy?

Authors:  Ida Martinelli; Valerio De Stefano; Pier Mannuccio Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-04-08       Impact factor: 32.419

Review 3.  Cardiovascular Disease Risk Among Transgender People with HIV.

Authors:  Madeline Cetlin; Evelynne S Fulda; Sarah M Chu; Ole-Petter R Hamnvik; Tonia Poteat; Markella V Zanni; Mabel Toribio
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-09       Impact factor: 5.071

4.  Proteomic landscape of bronchoalveolar lavage fluid in human immunodeficiency virus infection.

Authors:  Elizabeth V Nguyen; Sina A Gharib; Kristina Crothers; Yu-Hua Chow; David R Park; David R Goodlett; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

Review 5.  Human immunodeficiency virus-associated lung malignancies.

Authors:  Allison A Lambert; Christian A Merlo; Gregory D Kirk
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 6.  Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?

Authors:  Amy C Justice; Kristine M Erlandson; Peter W Hunt; Alan Landay; Paolo Miotti; Russell P Tracy
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

7.  Cardiovascular disease associated with the human immunodeficiency virus: an update.

Authors:  Thomas S Metkus; Todd T Brown; Wendy S Post
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-11

8.  HIV-Associated Venous Thromboembolism.

Authors:  Michele Bibas; Gianluigi Biava; Andrea Antinori
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

9.  von Willebrand Factor is elevated in HIV patients with a history of thrombosis.

Authors:  Lennert W J van den Dries; Rob A Gruters; Sascha B C Hövels-van der Borden; Marieke J H A Kruip; Moniek P M de Maat; Eric C M van Gorp; Marchina E van der Ende
Journal:  Front Microbiol       Date:  2015-03-11       Impact factor: 5.640

10.  Cerebral venous sinus thrombosis in HIV-infected patients: report of 2 cases.

Authors:  Julius Chacha Mwita; Kgomotso Baliki; Ludo Tema
Journal:  Pan Afr Med J       Date:  2013-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.